A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

LMNA-Related Dilated Cardiomyopathy Clinical Trial

Status Completed

Clinical Trial Summary

This is a Phase 2 pilot study, involving a 48-week treatment period, designed to test the effectiveness of investigational study drug ARRY-371797 in treating patients with symptomatic genetic dilated cardiomyopathy due to a lamin A/C gene mutation, and to further evaluate the drug's safety. Approximately 12 patients from the US will be enrolled in this study.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Cardiomyopathies
• Cardiomyopathy, Dilated
• LMNA-Related Dilated Cardiomyopathy

• NCT number: NCT02057341
• Study type: Interventional
• Source: Pfizer
• Status: Completed
• Phase: Phase 2
• Start date: February 2014
• Completion date: May 2016